Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes

Status Active, not recruiting

Clinical Trial Summary

Patients patients enrolled in this study have a Lymphoma caused by EBV (after bone marrow transplantation, organ transplantation or patient immunodeficient.

They will receive one to three injections of allogenic CTL specific EBV.

The purpose of this study is to ensure that these injections can not cause a GVH and to study what the side effects are and to see whether this therapy might help patients with Lymphoma.

Immunological monitoring will also be studied.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

EBV Associated Lymphoma

Clinical Trial Details

NCT number	NCT01823718
Study type	Interventional
Source	Nantes University Hospital
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	February 2007
Completion date	August 2014

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05011058` - An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas	Phase 2
	Recruiting	`NCT06391814` - Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)	N/A